Provecs Medical GmbH

provecs is pioneering next-generation tumor gene therapy to expose the tumor to the immune system. The Company´s proprietary enviro adenoviral platform enables the targeted delivery of up to four biologicals combined in one product, thereby activating both the innate and the adaptive immune system. provecs also has established a comprehensive proof-of-concept platform named exviro® for ex-vivo therapy simulation in primary human cancer tissues. exviro®allows the monitoring of immune processes by big data transcriptome profiling, bioinformatics, and tissue immune imaging technologies.